Skipping of FCER1G Exon 2 Is Common in Human Brain But Not Associated with the Alzheimer's Disease Genetic Risk Factor rs2070902.

IF 2.8 Q2 NEUROSCIENCES

Journal of Alzheimer's disease reports Pub Date : 2023-11-30 eCollection Date: 2023-01-01 DOI:10.3233/ADR-230076

Alyssa C Feldner, Andrew K Turner, James F Simpson, Steven Estus

{"title":"Skipping of FCER1G Exon 2 Is Common in Human Brain But Not Associated with the Alzheimer's Disease Genetic Risk Factor rs2070902.","authors":"Alyssa C Feldner, Andrew K Turner, James F Simpson, Steven Estus","doi":"10.3233/ADR-230076","DOIUrl":null,"url":null,"abstract":"Background: Understanding the mechanisms whereby genetic variants influence the risk of Alzheimer's disease (AD) may provide insights into treatments that could reduce AD risk.Objective: Here, we sought to test the hypothesis that a single nucleotide polymorphism (SNP) associated with AD risk, rs2070902, influences splicing of FCER1G exon 2.Methods: AD and non-AD brain samples were analyzed for FCER1G expression by genotyping, immunohistochemistry, immunofluorescence, and qPCR.Results: The protein encoded by FCER1G, FcRγ, is robustly expressed in microglia in both AD and non-AD brain. The FCER1G isoform lacking exon 2 (D2-FCER1G) was readily detectable. Moreover, the proportion of FCER1G expressed as this isoform was increased in brains with high AD neuropathology. However, the proportion of FCER1G expressed as the D2-FCER1G isoform was not associated with rs2070902 genotype.Conclusions: In summary, the proportion of FCER1G expressed as the D2-FCER1G isoform is increased with AD neuropathology but is not associated with rs2070902.","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"7 1","pages":"1313-1322"},"PeriodicalIF":2.8000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10741965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/ADR-230076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Understanding the mechanisms whereby genetic variants influence the risk of Alzheimer's disease (AD) may provide insights into treatments that could reduce AD risk.

Objective: Here, we sought to test the hypothesis that a single nucleotide polymorphism (SNP) associated with AD risk, rs2070902, influences splicing of FCER1G exon 2.

Methods: AD and non-AD brain samples were analyzed for FCER1G expression by genotyping, immunohistochemistry, immunofluorescence, and qPCR.

Results: The protein encoded by FCER1G, FcRγ, is robustly expressed in microglia in both AD and non-AD brain. The FCER1G isoform lacking exon 2 (D2-FCER1G) was readily detectable. Moreover, the proportion of FCER1G expressed as this isoform was increased in brains with high AD neuropathology. However, the proportion of FCER1G expressed as the D2-FCER1G isoform was not associated with rs2070902 genotype.

Conclusions: In summary, the proportion of FCER1G expressed as the D2-FCER1G isoform is increased with AD neuropathology but is not associated with rs2070902.

查看原文本刊更多论文

人脑中常见 FCER1G 第 2 外显子缺失，但与阿尔茨海默病遗传风险因子 rs2070902 无关。

背景：了解基因变异对阿尔茨海默病（AD）风险的影响机制可为降低阿尔茨海默病风险的治疗方法提供启示：目的：在此，我们试图检验与AD风险相关的单核苷酸多态性（SNP）rs2070902影响FCER1G外显子2剪接的假设：通过基因分型、免疫组织化学、免疫荧光和 qPCR 分析 AD 和非 AD 脑样本中 FCER1G 的表达：结果：FCER1G编码的蛋白FcRγ在AD和非AD大脑的小胶质细胞中均有强表达。缺失第2外显子的FCER1G异构体（D2-FCER1G）很容易被检测到。此外，在AD神经病理程度较高的大脑中，以这种异构体形式表达的FCER1G比例有所增加。然而，以D2-FCER1G异构体表达的FCER1G比例与rs2070902基因型无关：总之，FCER1G以D2-FCER1G同工酶形式表达的比例随AD神经病理学的发展而增加，但与rs2070902无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Alzheimer's disease reports

CiteScore

2.80

自引率

0.00%

发文量